Tag Archive for: CNS

Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi

/in

Neuraxpharm, the central nervous system (CNS) specialist, to acquire two portfolios of established products for CNS disorders, pain and vascular diseases Dusseldorf and Barcelona, July 12, 2022 – Neuraxpharm Group (“Neuraxpharm”) today announced that it has entered into a definitive agreement to acquire two product portfolios for CNS disorders, pain and vascular diseases from Sanofi. With […]

Read more

Neuraxpharm pursues growth strategy for business in Switzerland

/in

The leading European central nervous system specialty company expands its operations in the highly attractive Swiss market and introduces Jörg Gärtner as new country manager Dusseldorf and Liestal, May 3, 2022 – Neuraxpharm Group (Neuraxpharm) ignites the next level of their business in Switzerland to leverage the full potential of the important pharmaceutical market. After having […]

Read more

Neuraxpharm appoints Tom Coogan as new Country Manager for Ireland

/in

Europe’s leading central nervous system specialty company strengthens its management team in Ireland and reinforces its growth strategy Dusseldorf and Barcelona, March 15, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces that Tom Coogan has been appointed Country Manager for Ireland. The appointment reinforces […]

Read more

Neuraxpharm expands its business in Southeast Europe

/in

Acquisition of Brain Therapeutics with operations in Greece, Cyprus and the Balkan countries Dusseldorf and Barcelona, March 8th, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces the expansion of its business in Southeast Europe through the acquisition of Brain Therapeutics, a CNS-focused marketing and distribution […]

Read more

Muna Therapeutics appoints Dr. Niels Plath as Chief Scientific Officer

/in

Brings more than 15 years of CNS drug discovery and development experience Copenhagen, Denmark and Boston, US, 1st November 2021 – Muna Therapeutics (“Muna”), pioneering the development of novel, first-in-class small molecule therapeutics for neurodegenerative diseases, today announces the appointment of Dr. Niels Plath as Chief Scientific Officer. Read more…

Read more